Mankind Pharma Ltd (MANKIND) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company demonstrated a strong start to the fiscal year, achieving a 13% year-on-year revenue growth, driven by disciplined execution and improvements across key operating and financial metrics.
- The domestic business, a core segment, grew by 10.5% year-on-year, supported by a significant 15.8% increase in the chronic portfolio and a notable recovery in the acute business.
- A key strategic focus, the chronic therapies segment, continued to show strong momentum, with its share of the business (excluding BSV) increasing by 80 basis points year-on-year to 40%, moving closer to the medium-term target of 50%.
- The international business delivered robust performance with a 29% year-on-year growth, contributing significantly to the overall revenue increase.
- Profitability saw a marked improvement, with the EBITDA margin expanding by 250 basis points year-on-year to 26.3%, attributed to better gross margins and operating leverage.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.